Gemlapodect is under clinical development by Noema Pharma and currently in Phase II for Tourette Syndrome. According to GlobalData, Phase II drugs for Tourette Syndrome have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gemlapodect’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemlapodect overview
Gemlapodect is under development for the treatment of Tourette syndrome, childhood onset fluency disorder (stuttering). It is administered orally as hard gelatin capsules. It acts by targeting phosphodiesterase 10A (PDE10A).
Noema Pharma overview
Noema Pharma (Noema) is a biotechnology company that discovers and develops treatment for orphan diseases of brain and central nervous system. The company is developing NOE-101, a mGluR5 inhibitor for treatment of tuberous sclerosis complex (TSC) and severe pain in trigeminal neuralgia (TN). It is also investigating NOE-105, a PDE10A inhibitor that modulates dopamines D2 receptors to treat tourette syndrome. The company was funded by Sofinnova Partners, Glide healthcare, Invus, Roche, BioMed Partners and Polaris Partners. Noema is headquartered in Basel, Basel-Stadt, Switzerland.
For a complete picture of Gemlapodect’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
